NervGen Pharma Corp. (NGEN.V)
- Previous Close
3.5900 - Open
3.6000 - Bid 3.5800 x --
- Ask 3.5900 x --
- Day's Range
3.5600 - 3.6100 - 52 Week Range
1.6500 - 3.7500 - Volume
69,459 - Avg. Volume
56,049 - Market Cap (intraday)
254.845M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3600 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.97
NervGen Pharma Corp., a clinical-stage biotech company together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
www.nervgen.comRecent News: NGEN.V
View MorePerformance Overview: NGEN.V
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NGEN.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NGEN.V
View MoreValuation Measures
Market Cap
254.85M
Enterprise Value
237.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
98.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-95.24%
Return on Equity (ttm)
-8,460.20%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.01M
Diluted EPS (ttm)
-0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
17.27M
Total Debt/Equity (mrq)
4.10%
Levered Free Cash Flow (ttm)
-8.84M